Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-year extension study of FTY720 versus mycophenolate mofetil with Neoral and corticosteroids in adult de novo renal transplant recipients
2004-004377-28Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2004
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fingolimod, mycophenolate mofetil, cyclosporine and corticosteroids in kidney allograft rejection (3 arms), sponsored by Novartis. Primary endpoints: Biopsy proven acute rejection, Graft loss and 2 more. Started Dec 2004; status: completed.
02
Drugs
fingolimodmycophenolate mofetilcyclosporinecorticosteroids
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2004-004377-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004377-28.